In six patients diagnosed with MM, we found gain of function mutations in KRAS or NRAS, which are inclusion criteria for a clinical study (NCT03091257) of treatment with the BRAF inhibitor Dabrafenib and/or the MEK inhibitor Trametinib in patients with relapsed and/or refractory MM. The gene discussed is KRAS; the disease is Miyoshi myopathy.